A Randomised Phase II study comparing the efficacy of 5azacitidine alone versus combination therapy with lenalidomide and 5azacitidine in patients with higher risk myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML). (MDS04)

Dataset includes: Data for 160 patients with newly diagnosed MDS. Patients were randomised to receive lenalidomide and 5azacitidine or 5azacitidine alone Demographic data, diagnostic data, treatment data, outcome data and measures of supportive care during treatment, Eg transfusion requirements, QoL